Login / Signup

Italian Real-World Analysis of the Impact of Polypharmacy and Aging on the Risk of Multiple Drug-Drug Interactions (DDIs) in HCV Patients Treated with Pangenotypic Direct-Acting Antivirals (pDAA).

Stefano FagiuoliPierluigi ToniuttoNicola CoppolaDomenica Daniela AnconaMargherita AndrettaFausto BartoliniFulvio FerranteAlessandro LupiStefano PalcicFrancesca Vittoria RizziDavide ReGema Alvarez NietoCandido HernandezFrancesca FrigerioValentina PerroneLuca Degli EspostiAlessandra Mangia
Published in: Therapeutics and clinical risk management (2023)
This real-world analysis provided a thorough characterization on the burden of polymedication regimens in HCV patients treated with SOF/VEL or GLE/PIB that expose such patients to an increased risk of DDIs. In our sample population, SOF/VEL regimen was more frequently detected on elderly patients and on those with ≥2 comedications at risk of multi-DDI, ie, among patients characterized by higher rates of comorbidities and polypharmacy.
Keyphrases
  • hepatitis c virus
  • end stage renal disease
  • newly diagnosed
  • ejection fraction
  • chronic kidney disease
  • adverse drug
  • peritoneal dialysis
  • human immunodeficiency virus
  • computed tomography